|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...4748495051525354555657...39323933» |
- Bosulif (bosutinib) / Pfizer, Promacta (eltrombopag) / Novartis
Challenges Navigating Therapies and Dosings in the Modern Era of Tyrosine Kinase Inhibitors (TKIs) in Low-Resource Countries (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_562;
A bosutinib trial in first-line CML treatment (BFORE) used a reduced dose of bosutinib (400 mg daily) and demonstrated superiority for MMR at 12 months; however, lower doses of bosutinib have not yet been found to show clinically significant results (<200 mg). This case demonstrates that even a lower dose of bosutinib can induce a molecular response in patients with CML.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Chronic Lymphocytic Leukemia With Richter's Transformation Presented With Imminent Tumor Lysis Syndrome: Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_520;
Additionally, the patient received filgrastim for 5 days as primary prophylaxis for febrile neutrophilia before discharge. He was discharged with outpatient follow-up with the hematology-oncology and nephrology teams.
- BTK Inhibitors: A Double-Edged (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_519;
Despite the rarity of PBL in patients with CLL, this case underscores the importance of considering the potential for transformation, especially with the widespread use of BTKis. Further research is essential to elucidate the molecular mechanisms driving this transformation, facilitating the development of optimized treatment strategies and improving outcomes for patients with CLL at risk of PBL development.
- Venclexta (venetoclax) / Roche, AbbVie
Adverse Events During Single-Agent Phase of Venetoclax Therapy (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_516;
Out of the 42 patients, 13 received venetoclax and obinutuzumab and 14 received venetoclax and rituximab protocols. Venetoclax prescriptions longer than one month appear to be safe with a low likelihood of unexpected cytopenia during single-agent phase therapy.
- Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) vs Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-Up From the GLOW Study (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_514;
P3
Fixed-duration Ibr+Ven continued to show superior PFS and OS vs Clb+O. With Ibr+Ven, the PFS benefit was pronounced in patients with uIGHV with uMRD at EOT+3 and in patients with mIGHV regardless of MRD status at EOT+3.
- Imbruvica (ibrutinib) / AbbVie, J&J
Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_513;
This study shows that ibrutinib demonstrates high efficacy across different types of patients with high-risk genomic features, including those with del(17p) or TP53 mutations or uIGHV. Ibrutinib has better outcomes in high-risk patients than non-BTK inhibitors, while comparisons with other BTK inhibitors are limited by methodological considerations.
- Venclexta (venetoclax) / Roche, AbbVie, Imbruvica (ibrutinib) / AbbVie, J&J
6-Year Time to Next Treatment (TTNT) Extrapolation Curve for GLOW Study: First-Line Ibrutinib Plus Venetoclax (I+V) Offers Long Treatment-Free Period for Older Adult/Unfit Patients With Chronic Lymphocytic Leukemia (CLL) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_512;
Although these findings suggest a promising, longer treatment-free period for previously untreated older-adult and/or unfit patients with CLL, extrapolated results should be interpreted cautiously. Long-term studies are needed to further validate the effectiveness of this therapeutic strategy in real-world clinical settings.
- Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Real-World Comparative Outcomes of First-Line (1L) Venetoclax + Obinutuzumab (VenO) Versus Covalent Bruton's Tyrosine Kinase Inhibitors (BTKis) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_511;
For VenO versus BTKis + anti-CD20, median TTNT-D was not reached for either treatment. However, patients receiving VenO may experience the benefit of time off treatment until progression, while those on BTKis + anti-CD20 receive treatment continuously.
- Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_510;
This analysis suggested higher age (>65 years) and burden of comorbidity (CIRS >6) as risk factors for SPM development in CLL patients receiving targeted therapies. However, the heterogeneous patient cohort and small sample size warrant confirmation in larger studies.
- Campath (alemtuzumab) / Sanofi, Leukeran (chlorambucil) / GSK
T-Cell Prolymphocytic Leukemia: A Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_509;
Interventions: We started chlorambucil plus prednisone while waiting for alemtuzumab. He didn't respond and died 4 months later.
- Venclexta (venetoclax) / Roche, AbbVie, nemtabrutinib (MK-1026) / Merck (MSD), Rituxan (rituximab) / Roche
Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_507;
P3
Main Outcome Measures: The primary end point for part 1 is safety and the recommended dose of nemtabrutinib + venetoclax. The primary end point for part 2 is progression-free survival per iwCLL 2018 criteria; undetectable minimal residual disease in bone marrow at month 14, objective response rate, duration of response, overall survival, and safety are secondary.
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_502;
P1/2
Response rates were notably higher in patients without prior RT treatment. These promising data support continued evaluation of epcoritamab as a chemotherapy-free treatment option in RT.
- Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Monocytosis Developing in the Course of Chronic Lymphocytic Leukemia: Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_500;
Rituximab-venetoclax treatment was initiated...An increased AMC in CLL patients compared to normal controls indicates poor prognosis. This case highlights the significance of monitoring AMC in CLL patients as an indicator of disease progression and treatment response.
- Venclexta (venetoclax) / Roche, AbbVie, Imbruvica (ibrutinib) / AbbVie, J&J
Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_499;
Venetoclax-ibrutinib combination therapy demonstrates superior efficacy in terms of PFS and minimal residual disease compared to alternative treatments in CLL patients. Although associated with certain AEs, its safety profile is generally favorable.
- Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche
Chronic Lymphocytic Leukemia: Immune Dysregulation and Management: A Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_497;
IGRT may be required for patients with persistent infections and IgG levels below 500 mg/dL, especially when anti-infective treatments are ineffective. These case reports underscore the necessity of monitoring immunoglobulin levels and considering IGRT in managing CLL-related hypogammaglobulinemia.
- Breyanzi (lisocabtagene maraleucel) / BMS
Real-World Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients With Richter Transformation (RT) From the Center for International Blood and Marrow Transplant Research (CIBMTR) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_496;
Here, we show that liso-cel provided meaningful clinical benefit and manageable safety, with low incidences of grade ?3 CRS. The high CR rate is promising in this difficult-to-treat population, and longer follow-up in a larger cohort is needed.
- Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_492;
Real-world monthly costs among commercially insured patients with CLL were reduced by more than 70% beyond 12 months of fixed-duration VenO. This decline was not observed with ibrutinib or acalabrutinib, highlighting the economic benefit of fixed-duration VenO relative to BTKis.
- An Unusual Case of Renal Infiltration in Chronic Lymphocytic Leukemia (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_483;
With the advent of more targeted therapies for CLL, the risk of TLS becomes a crucial consideration, requiring proactive preventive measures. In clinical practice, both hematologists and nephrologists must be well-versed with various differentials leading to suboptimal renal function in patients with CLL, although uncommon renal infiltration of CLL is worth working up for in cases of inconclusive non-interventional workup as it might indicate disease recurrence/progression prompting the treatment change or resumption, and with the advent of advanced cancer therapies it can be reversible if caught early and treated cautiously.
- Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche
Patterns of Disease, Risk Factors, and Treatment in Chronic Lymphocytic Leukemia (CLL): A Retrospective Report of a Real-world Patient Cohort From the United Arab Emirates (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_481;
The number of patients is significantly less (3%) than the incidence in the Western hemisphere (35%) of all leukemia cases. Median age (59 years) is at least a decade younger than the Western hemisphere, with a preponderance in males.
- Myeloid Sarcoma and Lymphoid Sarcoma of the Brain: A Case Series (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_473;
Achieved imaging response of MS with fludarabine, idarubicin, cytarabine, and ponatinib...Treated with fludarabine, cytarabine, and venetoclax...BMB relapse after SCT was managed with miniCVD + inotuzumab + blinatumomab and she developed spinal leptomeningeal involvement at three years from presentation... CNS MS and LS are challenging, and treatment must be individualized.
- Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Hematological Malignancies and Pregnancy: A Single-Institution Experience (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_469;
Standard treatment induction regimens can be safely administered during the second or third trimester of pregnancy. Multispecialty management including maternal fetal medicine and malignant hematology specialists are of paramount importance.
- arsenic trioxide / Generic mfg.
Convenient Acute Promyelocytic Leukemia Consolidation Arsenic Trioxide Dosing Schedule (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_446;
This is the first report of successfully switching from APL0406 induction to AML17 consolidation. Adopting this regimen more widely could improve the quality of life for many APL patients.
- Iomab-B (I-131-apamistamab) / Actinium, Immedica
Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_440;
P3
Most patients achieving dCR are long-term survivors. Improved outcomes in Iomab-B-treated patients persisted at longer follow-up.
- Elzonris (tagraxofusp-erzs) / Menarini
Durable Outcomes and Manageable Safety with Tagraxofusp in a Real-World Study of Patients With Treatment-Na (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_414;
No new safety signals were observed. CLS was usually mild, manageable, and mostly limited to cycle 1.
- Darzalex (daratumumab) / J&J
The Role of Daratumumab in Treating Pure Red Cell Aplasia After Allogeneic Transplant in Patients With ABO Incompatibility: A Systematic Review (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_403;
Daratumumab exhibits substantial efficacy in treating PRCA post-allogeneic HSCT in patients with ABO incompatibility, with a high response rate and a favorable safety profile. However, further studies with larger cohorts and longer follow-up periods are necessary to validate these findings.
- magrolimab (ONO-7913) / Ono Pharma
Magrolimab Efficacy and Struggle for Approval in Acute Myeloid Leukemia: A Systematic Review (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_392;
The role of magrolimab in AML is under scrutiny. Further investigation is necessary to understand the lack of reproducibility of Phase 1 and 2 trial results in Phase 3 trial, resulting in the discontinuation of these studies.
- Scemblix (asciminib) / Novartis, Iclusig (ponatinib) / Takeda, Otsuka
Asciminib as a Bridge to Allogenic Transplant in 3 Patients With Relapsed/ Refractory Philadelphia Chromosome-positive ALL or CML Lymphoid Blast Crisis Refractory/Intolerant to Ponatinib (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_369;
One patient received BFM-90 induction + dasatinib 100mg...She was given 1 cycle of blinatumumab with asciminib, became MRD negative, and was taken up for haploidentical transplant... Mini-hyper-CVD with inotuzumab and asciminib is an effective salvage therapy for patients with Ph+ precursor B-ALL or CML lymphoid blast crisis who are refractory or intolerant to ponatinib, serving as a bridge to allogeneic transplant.
- Blincyto (blinatumomab) / Astellas, Amgen
Blinatumomab With Tyrosine Kinase Inhibitor for Ph-Positive B-Acute Lymphoblastic Leukemia (B-ALL): Multicenter Retrospective Review (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_362;
Although with short follow-up, combining TKI with blinatumomab seems to have a high CMR rate in patients with newly diagnosed and R/R Ph-positive B-ALL. Similar to prior reports, patients with newly diagnosed Ph-positive B-ALL perhaps could be spared the toxicities associated with chemotherapy and the need for allogeneic SCT.
- obecabtagene autoleucel (AUTO1) / Autolus
Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_351;
P1/2
Obecel's unique fast off-rate binder, administered using the TB-guided dosing strategy, resulted in substantial efficacy while protecting patients against onset of immunotoxicity. This supports the TB-guided dosing approach in adult R/R B-ALL.
- Rituxan (rituximab) / Roche
A High-Grade Dural Arteriovenous Fistula With Acute Lymphoblastic Leukemia After Bone Marrow Transplant for Multiple Myeloma: A Therapeutic Dilemma (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_331;
Chemotherapy with R-hyper-CVAD (rituximab, cyclophosphamide, vincristine, adriamycin, dexamethasone) with prophylactic intrathecal chemotherapy (methotrexate, cytarabine) was initiated. We describe the diagnosis, treatment, and management of a patient with both Cognard IV d-AVF and ALL, highlighting the complexities of managing 2 serious medical conditions simultaneously, necessitating multidisciplinary care coordination.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Adult Onset Familial Common B-Cell Acute Lymphoblastic Leukemia With Shared ZEB2 Mutation (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_327;
The pathogenic role of this abnormality is not clear, as it was associated with other, possibly pathogenic mutations, but it might have played a role in leukemogenesis. The patients were treated successfully with novel therapeutic regimens.
- Blincyto (blinatumomab) / Astellas, Amgen
Impact of Blinatumomab on Survival Outcomes in Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell ALL Following the Initial Phase of Pediatric-Inspired Chemotherapy: A Comparative Study (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_323;
Blinatumomab treatment may not only overcome the poor prognosis of post-consolidation MRD-positivity but also support a trend towards better EFS. We recommend larger, prospective trials with longer follow-up periods to validate these findings and determine the full clinical benefit of blinatumomab in the management of B-ALL.
- Blincyto (blinatumomab) / Astellas, Amgen
Comparable Outcomes of Relapsed Acute Lymphoblastic Leukemia in Adolescents and Young Adults (AYA) Treated With Pediatric-Inspired Chemotherapy (R3 Protocol) Versus Adult-Based Salvage (FA) Protocol (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_322;
Salvage treatment with blinatumomab for adults with relapsed B-cell ALL results in a complete remission (CR) rate of 34%, a median survival of 7.7 months, and an overall survival (OS) of less than 30% at 18 months...Therefore, this study aims to compare the outcomes of AYA patients treated with a pediatric-inspired regimen (R3 protocol) to those treated with an adult-based regimen (FA [fludarabine/ cytarabine] protocol)... Pediatric-inspired protocols that have shown significant benefits in the front-line setting for ALL in the AYA population did not demonstrate a significant difference when compared to traditional adult-based salvage chemotherapy regimens in relapsed disease.
- Blincyto (blinatumomab) / Astellas, Amgen
Blinatumomab in the Treatment of Relapsed Refractory B-ALL: Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_318;
Pediatric-inspired protocols that have shown significant benefits in the front-line setting for ALL in the AYA population did not demonstrate a significant difference when compared to traditional adult-based salvage chemotherapy regimens in relapsed disease. Our case illustrated that the single-agent blinatumomab is a safe and effective treatment in patients with refractory bone marrow relapse with blasts greater than 40% as a bridge therapy before Allo-HSCT.
- ||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion date: HIMALAYA: Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 30, 2024
P3, N=1324, Active, not recruiting, Sponsor: AstraZeneca
Our case illustrated that the single-agent blinatumomab is a safe and effective treatment in patients with refractory bone marrow relapse with blasts greater than 40% as a bridge therapy before Allo-HSCT. Trial completion date: Aug 2024 --> Aug 2026
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial: Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 30, 2024
P2, N=22, Not yet recruiting, Sponsor: University of Michigan Rogel Cancer Center
- |||||| Imfinzi (durvalumab) / AstraZeneca
Enrollment open: EDUR-BRA: A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil (clinicaltrials.gov) - Aug 30, 2024
P=N/A, N=60, Recruiting, Sponsor: AstraZeneca
Trial completion date: Aug 2024 --> Aug 2026 Not yet recruiting --> Recruiting
- ||| giredestrant (GDC-9545) / Roche
Trial completion date: A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) (clinicaltrials.gov) - Aug 30, 2024
P3, N=992, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial completion date: Mar 2027 --> Mar 2028
- | Tyvyt (sintilimab) / Eli Lilly
Phase classification, Trial completion date, Trial initiation date: Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC (clinicaltrials.gov) - Aug 30, 2024
P4, N=20, Not yet recruiting, Sponsor: Shanghai Chest Hospital
Trial completion date: Mar 2027 --> Mar 2028 Phase classification: P2 --> P4 | Trial completion date: Jul 2027 --> Oct 2027 | Initiation date: Jul 2024 --> Oct 2024
- | tobemstomig (RG6139) / Roche
Phase classification, Metastases: A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Aug 30, 2024
P2, N=80, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P2 --> P4 | Trial completion date: Jul 2027 --> Oct 2027 | Initiation date: Jul 2024 --> Oct 2024 Phase classification: P1/2 --> P2
- ||||||| Zejula (niraparib) / GSK, J&J, Tecentriq (atezolizumab) / Roche
Trial completion, Trial completion date, Trial primary completion date: ANITA: Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Aug 30, 2024
P3, N=417, Completed, Sponsor: Grupo Espa
Phase classification: P1/2 --> P2 Trial completion date: Jan 2024 --> Aug 2024 | Trial primary completion date: Jan 2024 --> Aug 2024 | Active, not recruiting --> Completed
- | ICG122 / iCell Gene Therap
Trial completion date: CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov) - Aug 30, 2024
P1, N=20, Recruiting, Sponsor: Huda Salman
Trial completion date: Jan 2024 --> Aug 2024 | Trial primary completion date: Jan 2024 --> Aug 2024 | Active, not recruiting --> Completed Trial completion date: Dec 2037 --> Dec 2040
- ||| sasanlimab (PF-06801591) / Pfizer
New P1 trial: A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer (clinicaltrials.gov) - Aug 30, 2024
P1, N=190, Not yet recruiting, Sponsor: Pfizer
- | LB-100 / Lixte Biotech, Tecentriq (atezolizumab) / Roche
Enrollment open: CoLBAt: LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Aug 30, 2024
P1, N=37, Recruiting, Sponsor: The Netherlands Cancer Institute
Trial completion date: Dec 2037 --> Dec 2040 Not yet recruiting --> Recruiting
- ||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion: A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista (clinicaltrials.gov) - Aug 30, 2024
P3, N=152, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion date: Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy (clinicaltrials.gov) - Aug 30, 2024
P2, N=32, Active, not recruiting, Sponsor: Institut f
Active, not recruiting --> Completed Trial completion date: Dec 2024 --> Dec 2025
- | Keytruda (pembrolizumab) / Merck (MSD), trabedersen (OT-101) - Autotelic, Oncotelic / Dragon Overseas JV
New P1/2 trial: Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 (clinicaltrials.gov) - Aug 30, 2024
P1/2, N=45, Not yet recruiting, Sponsor: University of Nebraska
- | Hansizhuang (serplulimab) / Fosun Pharma
New trial: Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 30, 2024
P=N/A, N=134, Not yet recruiting, Sponsor: Shanghai Chest Hospital
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD), IBI-310 (ipilimumab biosimilar) / Innovent Biologics
New P2 trial: Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers (clinicaltrials.gov) - Aug 30, 2024
P2, N=38, Recruiting, Sponsor: Peking University
- ||| GS-2121 / Gilead
Enrollment open: Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors (clinicaltrials.gov) - Aug 30, 2024
P1, N=154, Recruiting, Sponsor: Gilead Sciences
Trial completion date: Dec 2024 --> Dec 2025 Not yet recruiting --> Recruiting